Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Purinergic receptor P2Y12 inhibitor
DRUG CLASS:
Purinergic receptor P2Y12 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
YM-254890 (4)
YM-254890 (4)
›
Associations
(4)
News
Trials
Filter by
Latest
3d
RC31/23-0369: TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study (2023-509795-42-00)
P2/3, N=274, Not yet recruiting, Centre Hospitalier Universitaire De Toulouse
3 days ago
New P2/3 trial
5d
The Pharmacokinetics and Pharmacodynamics Study of CG-0255 Besylate and Plavix® in Healthy Participants (clinicaltrials.gov)
P1, N=136, Recruiting, Shanghai CureGene Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
5 days ago
Enrollment open
5d
COMFORT-PFO: Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy (clinicaltrials.gov)
P3, N=32, Not yet recruiting, Columbia University
5 days ago
New P3 trial
6d
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel (clinicaltrials.gov)
P1, N=24, Recruiting, Washington State University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
6 days ago
Trial completion date • Trial primary completion date
8d
The Pharmacokinetics and Pharmacodynamics Study of CG-0255 Besylate and Plavix® in Healthy Participants (clinicaltrials.gov)
P1, N=136, Not yet recruiting, Shanghai CureGene Pharmaceutical Co., Ltd.
8 days ago
New P1 trial
8d
EPIDAURUS: Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI (clinicaltrials.gov)
P4, N=602, Completed, Ludwig-Maximilians - University of Munich | Unknown status --> Completed | N=2334 --> 602 | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> May 2026
8 days ago
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
8d
To Compare the Pharmacodynamic and Short-term Clinical Effects of Standard DAPT, DAPT With Half-dose Ticagrelor, and Aspirin-free Half-dose Ticagrelor Monotherapy From the Day of PCI in Chronic Coronary Syndrome (CCS) (clinicaltrials.gov)
P4, N=60, Completed, Kaohsiung Veterans General Hospital.
8 days ago
New P4 trial
|
aspirin
8d
A Genomic Approach for Clopidogrel in Caribbean Hispanics (clinicaltrials.gov)
P1, N=150, Completed, University of Puerto Rico | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Dec 2025
8 days ago
Trial completion • Trial completion date
12d
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease (clinicaltrials.gov)
P=N/A, N=484, Recruiting, Massachusetts General Hospital
12 days ago
New trial
12d
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome (clinicaltrials.gov)
P4, N=17095, Completed, Vastra Gotaland Region | Recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025 | Trial primary completion date: Jan 2025 --> Aug 2025
12 days ago
Trial completion • Trial completion date • Trial primary completion date
12d
A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Viatris Innovation GmbH
12 days ago
New P1 trial
13d
BRAVE: Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (clinicaltrials.gov)
P=N/A, N=700, Recruiting, Population Health Research Institute | N=200 --> 700
13 days ago
Enrollment change
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.